DE69833459D1 - Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung - Google Patents
Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendungInfo
- Publication number
- DE69833459D1 DE69833459D1 DE69833459T DE69833459T DE69833459D1 DE 69833459 D1 DE69833459 D1 DE 69833459D1 DE 69833459 T DE69833459 T DE 69833459T DE 69833459 T DE69833459 T DE 69833459T DE 69833459 D1 DE69833459 D1 DE 69833459D1
- Authority
- DE
- Germany
- Prior art keywords
- mesothelin
- antibodies
- immunoconjugates
- molecules
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6717597P | 1997-12-01 | 1997-12-01 | |
US67175P | 1997-12-01 | ||
PCT/US1998/025270 WO1999028471A2 (en) | 1997-12-01 | 1998-11-25 | ANTIBODIES, INCLUDING Fv MOLECULES, AND IMMUNOCONJUGATES HAVING HIGH BINDING AFFINITY FOR MESOTHELIN AND METHODS FOR THEIR USE |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69833459D1 true DE69833459D1 (de) | 2006-04-20 |
DE69833459T2 DE69833459T2 (de) | 2006-08-17 |
Family
ID=22074202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69833459T Expired - Lifetime DE69833459T2 (de) | 1997-12-01 | 1998-11-25 | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1025230B1 (de) |
AT (1) | ATE317437T1 (de) |
AU (1) | AU760120B2 (de) |
CA (1) | CA2318576C (de) |
DE (1) | DE69833459T2 (de) |
ES (1) | ES2255194T3 (de) |
IL (2) | IL135775A0 (de) |
WO (1) | WO1999028471A2 (de) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001018542A2 (en) * | 1999-09-03 | 2001-03-15 | Millennium Pharmaceuticals, Inc. | Identification, assessment, prevention, and therapy of ovarian cancer |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
ES2349348T3 (es) * | 2000-01-27 | 2010-12-30 | Medimmune, Llc | Anticuerpos neutralizantes de rsv de ultra alta afinidad. |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US8022190B2 (en) | 2001-06-19 | 2011-09-20 | Technion Research & Development Foundation Ltd. | Immuno-molecules containing viral proteins, compositions thereof and methods of using |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US20090110702A1 (en) | 2002-07-12 | 2009-04-30 | The Johns Hopkins University | Mesothelin Vaccines and Model Systems and Control of Tumors |
US9200036B2 (en) | 2002-07-12 | 2015-12-01 | The Johns Hopkins University | Mesothelin vaccines and model systems |
US20050175625A1 (en) | 2002-07-12 | 2005-08-11 | The Johns Hopkins University | Mesothelin vaccines and model systems |
WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
EA200870555A1 (ru) * | 2006-05-19 | 2009-04-28 | Тева Фармасьютикал Индастриз, Лтд. | Слитые белки, их применение и способы их получения |
EP1997830A1 (de) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung |
SI2195017T1 (sl) | 2007-10-01 | 2015-01-30 | Bristol-Myers Squibb Company | Človeška protitelesa, ki vežejo mezotelin in njihova uporaba |
JP5608091B2 (ja) * | 2007-11-26 | 2014-10-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 抗メソセリン抗体およびその使用 |
AU2010230063B2 (en) * | 2009-03-24 | 2015-06-25 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Anti-mesothelin antibodies |
UY32560A (es) * | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
UA113838C2 (xx) | 2010-12-20 | 2017-03-27 | Антитіло, яке зв'язує мезотелін, та імунокон'югат | |
US8932586B2 (en) | 2011-09-06 | 2015-01-13 | Intrexon Corporation | Modified forms of Pseudomonas exotoxin A |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
WO2014182532A1 (en) * | 2013-05-07 | 2014-11-13 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Mesothelin-specific immunocytokine and use thereof |
US11161907B2 (en) | 2015-02-02 | 2021-11-02 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
EP3397756B1 (de) | 2015-12-30 | 2023-03-08 | Novartis AG | Immuneffektorzelltherapien mit verbesserter wirksamkeit |
US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
SI3443096T1 (sl) | 2016-04-15 | 2023-07-31 | Novartis Ag | Sestavki in postopki za selektivno izražanje himerni antigenskih receptorjev |
US20190161542A1 (en) | 2016-08-01 | 2019-05-30 | Novartis Ag | Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule |
ES2912408T3 (es) | 2017-01-26 | 2022-05-25 | Novartis Ag | Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos |
JP6339283B1 (ja) * | 2017-10-31 | 2018-06-06 | 国立大学法人 岡山大学 | Dna、ポリペプチド、抗メソセリン抗体、腫瘍イメージング剤及び複合体 |
US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
EP3788369A1 (de) | 2018-05-01 | 2021-03-10 | Novartis Ag | Biomarker zur auswertung von car-t-zellen zur vorhersage des klinischen ergebnisses |
WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019237035A1 (en) | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
JP2023529211A (ja) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | Zbtb32阻害剤及びその使用 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
WO2023006390A1 (en) | 2021-07-30 | 2023-02-02 | Ludwig-Maximilians-Universität München | Mesothelin antibodies and use thereof |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007081A2 (en) * | 1990-10-12 | 1992-04-30 | THE UNITED STATES OF AMERICA as represented by TH E SECRETARY, U.S. DEPARTMENT OF COMMERCE | A monoclonal antibody |
WO1997034634A1 (en) * | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
-
1998
- 1998-11-25 AT AT98961806T patent/ATE317437T1/de not_active IP Right Cessation
- 1998-11-25 CA CA002318576A patent/CA2318576C/en not_active Expired - Lifetime
- 1998-11-25 AU AU17041/99A patent/AU760120B2/en not_active Expired
- 1998-11-25 IL IL13577598A patent/IL135775A0/xx unknown
- 1998-11-25 EP EP98961806A patent/EP1025230B1/de not_active Expired - Lifetime
- 1998-11-25 DE DE69833459T patent/DE69833459T2/de not_active Expired - Lifetime
- 1998-11-25 ES ES98961806T patent/ES2255194T3/es not_active Expired - Lifetime
- 1998-11-25 WO PCT/US1998/025270 patent/WO1999028471A2/en active IP Right Grant
-
2000
- 2000-04-19 IL IL135775A patent/IL135775A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL135775A (en) | 2008-11-03 |
EP1025230A2 (de) | 2000-08-09 |
IL135775A0 (en) | 2001-05-20 |
CA2318576A1 (en) | 1999-06-10 |
EP1025230B1 (de) | 2006-02-08 |
AU760120B2 (en) | 2003-05-08 |
CA2318576C (en) | 2009-04-14 |
WO1999028471A3 (en) | 1999-07-29 |
ATE317437T1 (de) | 2006-02-15 |
WO1999028471A2 (en) | 1999-06-10 |
ES2255194T3 (es) | 2006-06-16 |
DE69833459T2 (de) | 2006-08-17 |
AU1704199A (en) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69833459D1 (de) | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung | |
ATE401348T1 (de) | Immunokonjugate mit hoher bindungsaffinität | |
DE69632401D1 (de) | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung | |
ATE446973T1 (de) | Anti-ccr2 antikörper sowie deren verwendung | |
EE04752B1 (et) | Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine | |
TR200301846T2 (tr) | Cripto bloke edici Antikorlar ve bu antikorların kullanımları. | |
HUT70471A (en) | Antitumor imunoconjugates, method for producing them, and pharmaceutical compositions containing the conjugates | |
DE69838979D1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
ATE85652T1 (de) | Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung. | |
ATE165395T1 (de) | Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen | |
SG96535A1 (en) | Pharmaceutical composition for the treatment or prevention of a malignant tumor | |
PT1157041E (pt) | Anticorpos para terapia e diagnostico de cancro | |
GR1000454B (el) | Νεο μονοκλωνικο αντισωμα κατα νεου αντιγονου που σχετιζεται με ανθρωπινους ογκους. | |
GR1000712B (el) | Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα. | |
IL94159A0 (en) | Recombinant antibody-toxin fusion protein | |
EE05497B1 (et) | Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha | |
NZ326436A (en) | Ligand directed enzyme prodrug therapy for tumours using ligands that recognise and bind tumour receptors | |
PT821060E (pt) | Mutacoes de e-caderina como base para o diagnostico e a terapia de tumores humanos malignos | |
DE69829001D1 (de) | Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72 | |
ATE490271T1 (de) | Rezeptor, dessen verwendung sowie mausantikörper | |
DE69724761D1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
NO20004251L (no) | Humaniserte anti-CEA monoklonale antistoffer med høy affinitet | |
ATE58397T1 (de) | Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen. | |
ATE156521T1 (de) | Monoklonaler antikörper zur differenzierung von ''squamous cell carcinoma''-antigenen und verfahren zu dessen verwendung | |
BR9815776A (pt) | Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |